Editor's Note: At 3:44, the speaker incorrectly stated that Zetia (ezetimibe) is an off-patent statin drug. Zetia is actually a cholesterol absorption inhibitor and its patent has not yet expired. The Fool regrets the error.

This episode of The Motley Fool's Market Checkup dives into the hottest headlines, looks at the biggest market movers in the health-care sector, and discusses the implementation of the Affordable Care Act, also known as Obamacare.

This segment from the show focuses on new data from a trial testing the efficacy of a new cholesterol-lowering drug from biotech Regeneron (NASDAQ:REGN) and its big pharma partner Sanofi (NYSE:SNY). Analysts David Williamson and Max Macaluso look at this emerging drug class and the implications for the wider cholesterol-lowering market.

Alison SouthwickMax Macaluso, Ph.D., and The Motley Fool have no position in any stocks mentioned. David Williamson owns shares of Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.